One study including 107 patients diagnosed with breast or ovarian cancer revealed that the c.5266dupC Ashkenazi founder mutation was the most common BRCA1 pathogenic variant reported in 36.67% of cases, closely followed by c.3607C>T in 30% of cases. This evidence concerns the gene BRCA1 and ovarian cancer.